NASDAQ:PBM Psyence Biomedical Q2 2027 Earnings Results & Report $2.86 +0.35 (+13.94%) Closing price 11/19/2026 04:00 PM EasternExtended Trading$2.87 +0.01 (+0.35%) As of 08:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Psyence Biomedical reported Q2 2027 earnings on November 19, 2026. The company reported EPS of -$0.24. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2027Report DateNovember 19, 2026TimeBefore Market Opens Psyence Biomedical EPS ResultsActual EPS-$0.24Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/APsyence Biomedical Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Psyence Biomedical Q2 2027 Earnings FAQ Did Psyence Biomedical beat earnings estimates for Q2 2027? Psyence Biomedical (NASDAQ:PBM) reported earnings of -$0.24 per share for Q2 2027. The report was announced on Thursday, November 19, 2026. Psyence Biomedical Earnings HeadlinesPsyence Biomedical Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2026November 19 at 1:26 PM | marketscreener.comMPsyence Biomedical Files September 30 Interim Financial StatementsNovember 19 at 9:51 AM | tipranks.comYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt death spiral. Interest payments alone now top a trillion dollars a year. The Social Security trust fund is projected to run dry by 2032, which could trigger an automatic 22% cut to benefits. Between 2020 and 2022, the Fed expanded the money supply by 41%. A free 27 page report breaks down these numbers in plain English, including what central banks have been doing with gold.November 20 at 1:00 AM | American Alternative (Ad)Psyence Biomedical Ltd. GAAP EPS of -$0.24November 19 at 8:30 AM | seekingalpha.comPsyence Biomedical (NASDAQ:PBM) Stock Falls 11.3% - Time to Sell?November 18 at 3:02 AM | americanbankingnews.comPsyence BioMed Completes PsyLabs Investment as Ibogaine Milestones Are MetOctober 21, 2026 | globenewswire.comSee More Psyence Biomedical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Psyence Biomedical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Psyence Biomedical and other key companies, straight to your email. Email Address About Psyence BiomedicalPsyence Biomedical (NASDAQ:PBM) is a clinical-stage biopharmaceutical company developing nature-derived psychedelic treatments for mental health and palliative care. Its research focuses on psilocybin, a psychedelic compound, for potential use in supervised therapeutic settings. The company’s lead candidate, PEX010, is a naturally derived psilocybin product being studied for adjustment disorder in people receiving palliative care. Psyence Biomedical’s work centers on clinical development and evaluating the safety and potential therapeutic effects of this treatment. Psyence Biomedical became a publicly traded company in 2024 through a business combination with Newcourt Acquisition Corp. It is part of the Psyence group, which has roots in psychedelic research and development.View Psyence Biomedical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting GameWalmart Earnings Change the Narrative as Digital Growth Lifts OutlookWhatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play ItHome Depot Posts a Q3 Double Beat, But Is Its Rebound Built to Last?Lowe's Earnings Beat Looked Strong Until a 34-Cent Tariff Refund Changed the MathApple's Next Margin Defense Could Be Hiding in Your WalletThe Uranium Price Paradox: 5 Investments Facing Very Different Tests in 2027 Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.